E

How will the RCC landscape change – who dares, wins?!

A look at the changing face of the RCC landscape, including current and near term trial readouts

February 13, 2018
E

The death of PD-L1 in urothelial cancer

As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?

February 12, 2018
E

Future directions in advanced prostate cancer

A look at some new targeted and IO combinations in development for advanced prostate cancer

February 9, 2018
E

Apalutamide is not a winner at ASCO GU

Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?

February 8, 2018
E

GU18 Preview – Promise and Pitfalls Abound

Highlights and Lowlights from ASCO GU 2018 - what to watch out for.

February 5, 2018
E

Go Forth and PROSPER

Interview with Dr Daniel George on Phase 3 PROSPER trial results

February 5, 2018
E

Immune Landscape of Pancreatic Cancer

A look at where we are in pancreatic cancer and how the landscape has evolved of late...

January 25, 2018
E

ASCO GI18 Preview

A look at 8 key abstracts being presented at #GI18 in San Francisco this week.

January 17, 2018